Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim with Danazol in Eltrombopag-resistant ITP
NCT04289207Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of romiplostim and danazol in immune thrombocytopenia (ITP), sponsored by Seoul National University Hospital. Primary endpoint: Response rate at 8 weeks. Status: unknown.
02
Drugs
romiplostimdanazol
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04289207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289207.